Aquestive Therapeutics Reports Third Quarter 2026 Financial Results
Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The earnings decline and lack of near‑term catalysts suggest short‑term weakness, but the NDA resubmission keeps long‑term upside potential alive.
Market read
Primary disclosure of earnings and regulatory update for a micro‑cap biotech; relevant for traders focused on biotech earnings and FDA pipeline news.
What to watch
Potential upside from upcoming commercial preparations and partnership with Eton could be underappreciated.
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Third-quarter revenue declined 41% to $7.6 million and non-GAAP adjusted EBITDA loss widened to $12.2 million, while the Anaphylm NDA resubmission was accepted with a March 16, 2027 PDUFA goal date and full-year 2026 guidance was maintained.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues, three months ended September 30, 2026GAAP | $7.6M | – | 41% decrease |
| Manufacture and supply revenue, three months ended September 30, 2026GAAP | $6.7M | – | – |
| License and royalty revenue, three months ended September 30, 2026GAAP | $800K | – | – |
| Manufacture and supply expense, three months ended September 30, 2026GAAP | $3.61M | – | – |
| Gross Margin on total revenue, three months ended September 30, 2026GAAP | 52 % | – | – |
| Non-GAAP adjusted manufacture and supply expenses, three months ended September 30, 2026non-GAAP | $3.40M | – | – |
| Non-GAAP Gross Margin on total revenue, three months ended September 30, 2026non-GAAP | 55 % | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $4.3M | – | – |
| Non-GAAP adjusted research and development expenses, three months ended September 30, 2026non-GAAP | $3.92M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $14.2M | – | – |
| Non-GAAP adjusted selling, general and administrative expenses, three months ended September 30, 2026non-GAAP | $12.43M | – | – |
| Total costs and expenses, three months ended September 30, 2026GAAP | $22.03M | – | – |
| Non-GAAP adjusted costs and expenses, three months ended September 30, 2026non-GAAP | $19.74M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$14.47M | – | – |
| Interest expense, three months ended September 30, 2026GAAP | −$1.84M | – | – |
| Interest expense related to royalty obligations, three months ended September 30, 2026GAAP | −$973K | – | – |
| Interest expense related to the sale of future revenue, three months ended September 30, 2026GAAP | −$62K | – | – |
| Interest income and other income, net, three months ended September 30, 2026GAAP | $853K | – | – |
| Net loss before income taxes, three months ended September 30, 2026GAAP | −$16.50M | – | – |
| Net loss, three months ended September 30, 2026GAAP | $16.5M | – | – |
| Basic and diluted loss per share, three months ended September 30, 2026GAAP | $0.13 for both basic and diluted loss per share | – | – |
| Weighted average common shares outstanding, basic and diluted, three months ended September 30, 2026GAAP | 125,548,783 (in shares) | – | – |
| Non-GAAP adjusted EBITDA loss, three months ended September 30, 2026non-GAAP | $12.2M | – | – |
| Non-GAAP adjusted EBITDA excluding Non-GAAP adjusted R&D expenses, three months ended September 30, 2026non-GAAP | −$8.27M | – | – |
| Revenues, nine months ended September 30, 2026GAAP | $35.82M | – | – |
| Gross Margin on total revenue, nine months ended September 30, 2026GAAP | 69 % | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$26.90M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$47.42M | – | – |
| Basic and diluted loss per share, nine months ended September 30, 2026GAAP | $(0.38) (in dollars per share) | – | – |
| Non-GAAP adjusted EBITDA, nine months ended September 30, 2026non-GAAP | −$19.15M | – | – |
| Non-GAAP Gross Margin on total revenue, nine months ended September 30, 2026non-GAAP | 71 % | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Manufacture and supply revenueDecreases in Suboxone revenues due to timing of product orders, partially offset by higher Ondif revenues. | $6.7M | – | – |
| License and royalty revenueLower estimated royalty revenues. | $800K | – | – |
full-year 2026 outlook
- Revenue$46 to $50 (in millions)
- NoteNon-GAAP adjusted EBITDA loss (in millions) $35 to $30
What drove it
- The 41% decrease in total revenues was primarily driven by the quarterly fluctuation of Suboxone product orders.
- The Company manufactured approximately 26 million doses in the third quarter 2026, compared to approximately 44 million doses in the third quarter 2025.
- On a year-to-date basis through September, the Company manufactured approximately 107 million doses in 2026 compared to approximately 108 million doses in the same period in 2025.
- Research and development expense declined primarily due to lower share-based compensation, partially offset by higher clinical trial costs from the human factors validation study and PK study completed for the Anaphylm NDA resubmission.
- Selling, general and administrative expense declined primarily due to lower legal fees of approximately $1.5 million, lower commercial spending of approximately $1.4 million, and lower regulatory expenses related to Anaphylm of approximately $0.6 million.
- In October 2026, Aquestive granted Eton Pharmaceuticals, Inc. exclusive U.S. commercialization rights to Libervant and received a $10 million upfront payment.
Concerns
- Revenue fell to $7.6 million from $12.8 million as Suboxone product ordering timing reduced manufacture and supply revenue.
- Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.
- Net loss increased to $16.5 million from $15.4 million.
- Anaphylm approval remains subject to FDA review, with a PDUFA goal date of March 16, 2027.
- The filing identifies risks including eroding market share for Suboxone® and potential FDA requests for additional information, analyses, studies or inspections for Anaphylm.
What to watch
- FDA review of the Anaphylm Class 2 NDA resubmission ahead of the March 16, 2027 PDUFA goal date.
- Expected Health Canada submission in Q4 2026 and planned European Union filing in Q1 2027 for Anaphylm.
- Additional AQST-108 clinical work expected to begin in the first quarter of 2027.
- Final FDA action for Libervant patients twelve years of age and older, with a PDUFA goal date of March 23, 2027.
- FDA review of the Type 9 NDA for Libervant patients six to eleven years of age, with a PDUFA goal date of March 29, 2027.
- Execution of Eton Pharmaceuticals’ U.S. commercialization of Libervant and potential contingent milestone and royalty payments.
Balance sheet and cash flow
- Cash and cash equivalents were $90.3 million as of September 30, 2026.
- Cash and cash equivalents were $ 90,349 (In thousands) at September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025.
- Debt, current was $ 33 (In thousands) at September 30, 2026, compared with $ 9,994 (In thousands) at December 31, 2025.
- Debt, long-term, net was $ 50,757 (In thousands) at September 30, 2026, compared with $ 27,519 (In thousands) at December 31, 2025.
- Royalty obligations, net were $ 28,702 (In thousands) at September 30, 2026, compared with $ 25,941 (In thousands) at December 31, 2025.
- Liability related to the sale of future revenue, net was $ 61,192 (In thousands) at September 30, 2026, compared with $ 62,023 (In thousands) at December 31, 2025.
Analysis
Aquestive reported a weaker third quarter on its existing commercial business. Total revenues decreased to $7.6 million from $12.8 million, a 41% decrease that the company attributed primarily to quarterly fluctuation in Suboxone product orders. Manufacture and supply revenue decreased to $6.7 million from $11.5 million, while license and royalty revenue decreased to $0.8 million from $1.0 million. Manufacturing volume was approximately 26 million doses, compared with approximately 44 million doses in the prior-year quarter.
The lower revenue base pressured profitability. GAAP gross margin on total revenue was 52%, compared with 65%, and non-GAAP gross margin was 55%, compared with 67%. The operating loss was $(14,469) (In thousands), compared with $(11,479) (In thousands). Net loss was $16.5 million, or $0.13 for both basic and diluted loss per share, compared with $15.4 million, or $0.14 for both basic and diluted loss per share. Non-GAAP adjusted EBITDA loss widened to $12.2 million from $8.6 million.
Cost control partly offset the revenue decline. Research and development expenses decreased to $4.3 million from $4.5 million, reflecting lower share-based compensation partly offset by higher clinical trial costs for Anaphylm studies. Selling, general and administrative expenses decreased to $14.2 million from $15.3 million, driven by lower legal fees, commercial spending and Anaphylm regulatory expenses, partly offset by higher personnel, share-based compensation, consulting and outside-services expenses. For the nine months ended September 30, 2026, revenues were $35,822 (In thousands) versus $31,530 (In thousands), while net loss was $(47,417) (In thousands) versus $(51,924) (In thousands).
The central business development was FDA acceptance of the Anaphylm NDA resubmission as a Class 2 response, with a March 16, 2027 PDUFA goal date. The company is progressing launch preparation, expects a Health Canada submission in Q4 2026 and plans an EU filing in Q1 2027. In a separate commercial development, Eton received exclusive U.S. commercialization rights to Libervant, paid Aquestive a $10 million upfront payment, and may generate up to $47.5 million in contingent regulatory and sales-based milestones plus mid-teens royalties on net sales. Aquestive remains the exclusive manufacturer and supplier under a 20-year supply agreement.
Liquidity stood at $90.3 million of cash and cash equivalents as of September 30, 2026, compared with $ 121,169 (In thousands) at December 31, 2025. Long-term debt, net was $ 50,757 (In thousands), and the liability related to the sale of future revenue, net was $ 61,192 (In thousands). Full-year 2026 guidance was unchanged at total revenue of $46 to $50 (in millions) and non-GAAP adjusted EBITDA loss of $35 to $30 (in millions).
Management, verbatim
With a PDUFA goal date of March 16, 2027, we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved.
Daniel Barber, President and Chief Executive Officer
Not in the filing
stated, not guessed- Previous-period outlook was not provided, so comparison of actual results with prior guidance is unavailable.
- Quarterly operating cash flow was not reported.
- Quarterly free cash flow was not reported.
- Share repurchases, dividends and other capital-return activity were not reported.
- Total debt as a single line item was not reported; current debt and long-term debt, net were reported separately.
- A GAAP tax rate was not reported.
- Quarter-over-quarter comparisons were not reported for the financial metrics.
- Separate reported business-segment revenue beyond manufacture and supply revenue and license and royalty revenue was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
AQST is a Nasdaq‑listed biotech focused on epinephrine delivery platforms. The 8‑K provides its first quarterly financials for Q3 2026 and updates on its lead candidate Anaphylm.
Ticker impact
AQST filed an 8‑K reporting Q3 2026 results, showing a 41% revenue drop and an NDA resubmission with a PDUFA date of March 16 2027.
likely pressure as the market prices in lower revenue and delayed product approval
Revenue fell sharply and the only catalyst is a resubmitted NDA with a future PDUFA date, offering no immediate upside.
Market effects
Highlights continued risk in the niche oral epinephrine biotech space.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond niche biotech sector.
Counterpoint
If the NDA resubmission is viewed as a step toward approval, the stock could rally on future upside.
Key entities
- companyAquestive Therapeutics, Inc.
Nasdaq‑listed biotech reporting Q3 2026 results.
- companyEton Pharmaceuticals, Inc.
Partner receiving exclusive U.S. rights to Libervant.


